.jpg "Amit Gefen, PhD photo")
Full Professor with the Department of Biomedical Engineering
Faculty of Engineering of Tel Aviv University
Tel Aviv, Tel Aviv, Israel
The research interests of Prof. Gefen are in studying normal and pathological effects of biomechanical factors on the structure and function of cells, tissues and organs, with emphasis on applications in chronic wound research. In 2007-2008 he was a visiting scientist at Eindhoven University of Technology, where he developed tissue-engineered model systems to study pressure ulcers. To date, Prof. Gefen published more than 300 articles in peer-reviewed international journals, many of which on mechanobiology, cell and tissue biomechanics, with applications in wound care. Prof. Gefen was awarded the Pressure Care career award by the World Union of Wound Healing Societies in 2016, the Experienced Investigator Award of EPUAP in 2017 and the Otto Schmitt Career Award of the International Federation of Medical & Biological Engineering in 2018 for “exceptional contributions to the advancement of the field of medical and biological engineering”. Recently, Prof. Gefen has chaired the Etiology expert panel for development of the International Pressure Ulcer Prevention & Treatment Guidelines (2019) and the global panel of experts who developed the International Consensus Document for Device-related Pressure Ulcers, published by the Journal of Wound Care (2020). Prof. Gefen had visiting professorship appointments and fellowships in multiple UK universities including Cambridge University (the Isaac Newton Institute), University of Southampton (Distinguished Fellowship through the Royal Academy of Engineering) and the University of Huddersfield, as well as at the University of Cape Town in South Africa and at the Katholieke Universiteit Leuven (KU Leuven) in Belgium. His research has been funded for example by the European Commission (EC), the Israel Science Foundation, the Israeli goveronment as well as international corporates. Prof. Gefen is advising and reviewing for journals such as Lancet and Nature, for funding bodies worldwide including the EC, and to the global medical device industry.
I do not have any relevant financial / non-financial relationships with any proprietary interests.
Tuesday, March 22, 2022
8:35 AM – 9:05 AM CDT
Friday, March 25, 2022